Profiling of the calcitonin-calcitonin receptor axis in primary prostate cancer: clinical implications and molecular correlates

Thakkar,Arvind; Bijnsdorp,Irene   V.; Geldof,Albert  A.; Shah,Girish  V.

doi:10.3892/or.2013.2583

Profiling of the calcitonin-calcitonin receptor axis in primary prostate cancer: clinical implications and molecular correlates

Authors:
- Arvind Thakkar
- Irene V. Bijnsdorp
- Albert A. Geldof
- Girish V. Shah
View Affiliations

Affiliations: Department of Pharmacology, University of Louisiana, College of Pharmacy, Monroe, LA 71291, USA, Department of Urology, VU University Medical Center, Amsterdam, the Netherlands
Published online on: July 2, 2013 https://doi.org/10.3892/or.2013.2583
Pages: 1265-1274

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression of the neuroendocrine peptide calcitonin (CT) and its receptor (CTR) is frequently elevated in prostate cancers (PCs), and activation of the CT-CTR axis in non-invasive PC cells induces an invasive phenotype. We aimed to link CT/CTR expression in prostate specimens to clinicopathological parameters of PC. We analyzed CT and CTR expression in cohorts of benign prostates and primary PCs with/without metastatic disease by immunohistochemistry. Furthermore, we correlated CT/CTR expression with several clinicopathological parameters. CT/CTR immunostaining in benign prostate acini was predominantly localized to basal epithelium. However, this spatial specificity was lost in malignant prostates. PC sections displayed a remarkable increase in cell populations expressing CT/CTR and their staining intensity. Tumors with higher CT/CTR expression consistently displayed metastatic disease and poor clinical outcome. High CT/CTR expression in primary prostate tumors may serve as a prognostic indicator of disease aggressiveness and poor clinical outcome.

View Figures

View References

1	Horwich A, Parker C and Kataja V: Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 20(Suppl 4): S76–S78. 2009. View Article : Google Scholar
2	Armstrong AJ and Febbo PG: Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Oncologist. 14:816–827. 2009.PubMed/NCBI
3	Deng B, Zhang S, Miao Y, et al: Adrenomedullin expression in epithelial ovarian cancers and promotes HO8910 cell migration associated with upregulating integrin alpha5beta1 and phosphorylating FAK and paxillin. J Exp Clin Cancer Res. 31:192012. View Article : Google Scholar : PubMed/NCBI
4	Wang X, Nakamura M, Mori I, et al: Calcitonin receptor gene and breast cancer: quantitative analysis with laser capture microdissection. Breast Cancer Res Treat. 83:109–117. 2004. View Article : Google Scholar : PubMed/NCBI
5	Delis S, Bakoyiannis A, Giannakou N, Tsigka A, Avgerinos C and Dervenis C: Asymptomatic calcitonin-secreting tumor of the pancreas. A case report. JOP. 7:70–73. 2006.PubMed/NCBI
6	Ferrigno D, Buccheri G and Biggi A: Serum tumour markers in lung cancer: history, biology and clinical applications. Eur Respir J. 7:186–197. 1994. View Article : Google Scholar : PubMed/NCBI
7	Shah GV, Noble MJ, Austenfeld M, Weigel J, Deftos LJ and Mebust WK: Presence of calcitonin-like immunoreactivity (iCT) in human prostate gland: evidence for iCT secretion by cultured prostate cells. Prostate. 21:87–97. 1992. View Article : Google Scholar : PubMed/NCBI
8	Thomas S, Chigurupati S, Anbalagan M and Shah G: Calcitonin increases tumorigenicity of prostate cancer cells: evidence for the role of protein kinase A and urokinase-type plasminogen receptor. Mol Endocrinol. 20:1894–1911. 2006. View Article : Google Scholar
9	Chien J, Ren Y, Qing Wang Y, et al: Calcitonin is a prostate epithelium-derived growth stimulatory peptide. Mol Cell Endocrinol. 181:69–79. 2001. View Article : Google Scholar : PubMed/NCBI
10	Conner AC, Simms J, Hay DL, et al: Heterodimers and family-B GPCRs: RAMPs, CGRP and adrenomedullin. Biochem Soc Trans. 32:843–846. 2004. View Article : Google Scholar : PubMed/NCBI
11	Purdue BW, Tilakaratne N and Sexton PM: Molecular pharmacology of the calcitonin receptor. Receptors Channels. 8:243–255. 2002. View Article : Google Scholar : PubMed/NCBI
12	Tolcos M, Tikellis C, Rees S, Cooper M and Wookey P: Ontogeny of calcitonin receptor mRNA and protein in the developing central nervous system of the rat. J Comp Neurol. 456:29–38. 2003. View Article : Google Scholar : PubMed/NCBI
13	Wookey PJ, McLean CA, Hwang P, et al: The expression of calcitonin receptor detected in malignant cells of the brain tumour glioblastoma multiforme and functional properties in the cell line A172. Histopathology. 60:895–910. 2012. View Article : Google Scholar : PubMed/NCBI
14	Shah GV, Thomas S, Muralidharan A, et al: Calcitonin promotes in vivo metastasis of prostate cancer cells by altering cell signaling, adhesion, and inflammatory pathways. Endocr Relat Cancer. 15:953–964. 2008. View Article : Google Scholar : PubMed/NCBI
15	Chigurupati S, Kulkarni T, Thomas S and Shah G: Calcitonin stimulates multiple stages of angiogenesis by directly acting on endothelial cells. Cancer Res. 65:8519–8529. 2005. View Article : Google Scholar : PubMed/NCBI
16	Jackel MC, Mitteldorf C, Schweyer S and Fuzesi L: Clinical relevance of Fas (APO-1/CD95) expression in laryngeal squamous cell carcinoma. Head Neck. 23:646–652. 2001. View Article : Google Scholar : PubMed/NCBI
17	Shah GV, Muralidharan A, Gokulgandhi M, Soan K and Thomas S: Cadherin switching and activation of β-catenin signaling underlie proinvasive actions of calcitonin-calcitonin receptor axis in prostate cancer. J Biol Chem. 284:1018–1030. 2009.
18	Brawer MK: Prostatic intraepithelial neoplasia: an overview. Rev Urol. 7(Suppl 3): S11–S18. 2005.
19	Thomas S and Shah G: Calcitonin induces apoptosis resistance in prostate cancer cell lines against cytotoxic drugs via the Akt/survivin pathway. Cancer Biol Ther. 4:1226–1233. 2005. View Article : Google Scholar : PubMed/NCBI
20	Ritchie CK, Thomas KG, Andrews LR, Tindall DJ and Fitzpatrick LA: Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate. 30:183–187. 1997. View Article : Google Scholar : PubMed/NCBI
21	Shah GV, Rayford W, Noble MJ, et al: Calcitonin stimulates growth of human prostate cancer cells through receptor-mediated increase in cyclic adenosine 3′,5′-monophosphates and cytoplasmic Ca²⁺ transients. Endocrinology. 134:596–602. 1994.PubMed/NCBI
22	Goodman MT, Ferrell R, McDuffie K, et al: Calcitonin gene polymorphism CALCA-624 (T/C) and ovarian cancer. Environ Mol Mutagen. 46:53–58. 2005. View Article : Google Scholar : PubMed/NCBI
23	Trimboli P, Rossi F, Baldelli R, et al: Measuring calcitonin in washout of the needle in patients undergoing fine needle aspiration with suspicious medullary thyroid cancer. Diagn Cytopathol. 40:394–398. 2012. View Article : Google Scholar : PubMed/NCBI
24	Hebden C, Smalt R, Chambers T and Pondel MD: Multiple promoters regulate human calcitonin receptor gene expression. Biochem Biophys Res Commun. 272:738–743. 2000. View Article : Google Scholar : PubMed/NCBI
25	Silverman AL, Park JG, Hamilton SR, Gazdar AF, Luk GD and Baylin SB: Abnormal methylation of the calcitonin gene in human colonic neoplasms. Cancer Res. 49:3468–3473. 1989.PubMed/NCBI
26	Shah GV: Calcitonin. Encyclopedia of Cancer. 2:16–20. 2009.
27	Yigitbasi O, Ozturk U, Goktug HN, Gucuk A and Bakirtas H: Prognostic factors in metastatic prostate cancer. Urol Oncol. 29:162–165. 2011. View Article : Google Scholar : PubMed/NCBI
28	Andren O, Fall K, Franzen L, Andersson SO, Johansson JE and Rubin MA: How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol. 175:1337–1340. 2006.PubMed/NCBI
29	Masieri L, Lanciotti M, Gontero P, et al: The prognostic role of preoperative chromogranin A expression in prostate cancer after radical prostatectomy. Arch Ital Urol Androl. 84:17–21. 2012.PubMed/NCBI
30	Gao J, Arnold JT and Isaacs JT: Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res. 61:5038–5044. 2001.